UPDATED May 20, 2016, with more results out of Paris. St. Jude Medical (NYSE:STJ) announced it won CE Mark approval in the European Union for its PressureWire X Guidewire fractional flow reserve measurement system and is launching the product in Europe. The company announced the launch and clearance at the EuroPCR meeting in Paris this week. […]
InspireMD
InspireMD opens $1.7 million in offerings to support embolic tech
InspireMD (OTC:NSPR) said today it is opening an underwritten public offering looking to bring in approximately $1.1 million through the sale of 1.9 million shares to support its CGuard EPS and MGuard Prime EPS. The Boston-based company said it will offer up 1.9 million shares of common stock at 59¢ per share, with warrants issued for the […]
InspireMD CEO Milinazzo, CTO Bar to bow out | Personnel Moves
InspireMD (OTC:NSPR) said today that it’s looking for a replacement for CEO Alan Milinazzo as it looks to drill down on the largest markets for its CGuard and MGuard stents, which are designed to help prevent blood clots that can cause stroke. Milinazzo agreed to stay on until either a replacement is found or June 30, […]
EU OKs add’l delivery cath for InspireMD’s CGuard stent
InspireMD (OTC:NSPR) said Wednesday it won European Union regulatory approval, including CE Mark approval, for the manufacturing and commercialization of its CGuard stent delivery catheter. The approval also allows InspireMD to add-on manufacturing facilities for the device to enable more efficient work flow, the Boston-based company said. “We are pleased to receive Dekra certification for our […]
InspireMD pulls trigger on 10-for-1 reverse stock split
InspireMD (OTC:NSPR) said it pulled the trigger on a reverse 10-to-1 stock split with shareholders receiving 1 share of common stock for each 10 they own. The reverse split went into effect today for the Boston-based stent maker, according to a press release. In response, Inspire shares are down 11.8% to $1.45 in mid-day trading. The […]
Tandem Diabetes plans $60m offering | Medtech funding for the week of March 2, 2015
InspireMD seeks to raise $8m in direct offering
Kimberly-Clark plans to spin out Halyard Health as a separately traded company | Medtech Wall Street news for the week of October 13, 2014
InspireMD drops MGuard stent in the U.S., shares slide
Abiomed touts survival rates for its Impella right-side heart pump | TCT 2014 Roundup
Abiomed (NSDQ:ABMD) got some Wall Street love today after releasing positive outcomes from a clinical trial of its minimally invasive Impella Right Percutaneous heart pump.
Researchers reported an overall 73% 30-day survival rate in the small study of patients with right ventricular heart failure, according to data Abiomed released during the Transcatheter Cardiovascular Therapeutics conference in Washington D.C.